Apellis Pharmaceuticals, Inc.
APLS
Classement en actions
#3323
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical... Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), which is being developed for a range of indications: in hematology for cold agglutinin disease (CAD) and thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA); in nephrology for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); and in neurology for amyotrophic lateral sclerosis (ALS). Furthermore, Apellis boasts a diverse pipeline including APL-2006, a dual-action C3 and VEGF inhibitor designed for complement-mediated disorders; APL-1030, a C3 inhibitor targeting multiple neurodegenerative diseases; and a novel combination therapy involving EMPAVELI with small interfering RNA (siRNA) to reduce hepatic C3 protein synthesis. Strategic alliances play a significant role, with a collaboration and licensing agreement in place with Swedish Orphan Biovitrum AB (publ) for the joint development of pegcetacoplan. The company also maintains a research partnership with Beam Therapeutics Inc., focusing on leveraging Beam's base editing technology to uncover new treatments for illnesses driven by complement system dysregulation. Established in 2009, Apellis Pharmaceuticals, Inc. operates from its headquarters in Waltham, Massachusetts.
Prix de l'action
$41.03
Dernière synchronisation: 2026-05-15
Capitalisation boursière
$5.25B
Changement (1 jour)
0.00%
Changement (1 an)
51.57%
Pays
US
Échange Apellis Pharmaceuticals, Inc. (APLS)
Catégorie
Healthcare
Bénéfices pour Apellis Pharmaceuticals, Inc. (APLS)
Bénéfices en Mar 2026 TTM : $135.15M
Selon les derniers rapports financiers de Apellis Pharmaceuticals, Inc., les bénéfices actuels de l'entreprise sont de $135.15M. En 2023, l'entreprise a réalisé un bénéfice de $-526.50M, une augmentation par rapport à celui de 2022 qui était de $-651.50M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Apellis Pharmaceuticals, Inc. de 2013 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $135.15M | -168.70% |
| 2024 | $-196.72M | -62.64% |
| 2023 | $-526.50M | -19.19% |
| 2022 | $-651.50M | -12.67% |
| 2021 | $-746.00M | 117.47% |
| 2020 | $-343.03M | 12.58% |
| 2019 | $-304.71M | 138.98% |
| 2018 | $-127.50M | 149.97% |
| 2017 | $-51.01M | 88.04% |
| 2016 | $-27.13M | -41.69% |
| 2015 | $-46.52M | 314.14% |
| 2014 | $-11.23M | 183.49% |
| 2013 | $-3.96M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $5.27B | 3,803.11% |
US
|
|
| $-3.09B | -2,384.20% |
US
|
|
| $-4.02B | -3,071.75% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 1,343.37% |
NL
|
